Abstract
1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have